{"id":29240,"date":"2023-06-02T01:06:08","date_gmt":"2023-06-01T23:06:08","guid":{"rendered":"http:\/\/www.infokuryr.cz\/n\/?p=29240"},"modified":"2023-06-01T14:05:12","modified_gmt":"2023-06-01T12:05:12","slug":"uspesne-testovani-naplasti-s-mikrojehlovou-vakcinou-pro-kojence-sponzorovane-billem-gatesem-usnadni-globalni-distribuci-vakciny","status":"publish","type":"post","link":"https:\/\/www.infokuryr.cz\/n\/2023\/06\/02\/uspesne-testovani-naplasti-s-mikrojehlovou-vakcinou-pro-kojence-sponzorovane-billem-gatesem-usnadni-globalni-distribuci-vakciny\/","title":{"rendered":"\u201e\u00dasp\u011b\u0161n\u00e9\u201c testov\u00e1n\u00ed \u201en\u00e1plasti s mikrojehlovou vakc\u00ednou\u201c pro kojence sponzorovan\u00e9 Billem Gatesem usnadn\u00ed glob\u00e1ln\u00ed distribuci vakc\u00edny"},"content":{"rendered":"
<\/div>\n
\n
\n

Biotechnologick\u00e1 spole\u010dnost se s\u00eddlem v Atlant\u011b minul\u00fd t\u00fdden ozn\u00e1mila, \u017ee s podporou nadace Bill & Melinda Gates Foundation \u00fasp\u011b\u0161n\u011b dokon\u010dila v\u016fbec prvn\u00ed klinickou zkou\u0161ku vakc\u00edny bez injekce microarray u d\u011bt\u00ed ve v\u011bku 9 m\u011bs\u00edc\u016f.<\/strong><\/span><\/p>\n

Micron Biomedical testoval mikrojehli\u010dkovou aplikaci vakc\u00edny proti spalni\u010dk\u00e1m zard\u011bnk\u00e1m (MR) d\u011btem v Gambii s podporou Bill & Melinda Gates Foundation a Centers for Disease Control and Prevention (CDC).<\/span><\/p>\n

Microarray injekce se pod\u00e1vaj\u00ed pomoc\u00ed mikrojehlov\u00e9 n\u00e1plasti, kter\u00e1 vypad\u00e1 jako n\u00e1plast a na k\u016f\u017ei se aplikuje stla\u010den\u00edm.\u00a0Po p\u0159ipojen\u00ed proniknou mikrojehly horn\u00ed vrstvou k\u016f\u017ee a dodaj\u00ed vakc\u00ednu.<\/span><\/p>\n

Studie, kterou v\u011bdci minul\u00fd t\u00fdden p\u0159edstavili na konferenci Microneedles 2023 v Seattlu, hodnotila bezpe\u010dnost, imunogenicitu a p\u0159ijatelnost hlavn\u00ed komer\u010dn\u011b dostupn\u00e9 MR vakc\u00edny Indick\u00e9ho s\u00e9rum, kter\u00e1 byla vyrobena pomoc\u00ed technologie Micron’s microarray u dosp\u011bl\u00fdch, kojenc\u016f a d\u011bt\u00ed. kojenc\u016fm.<\/span><\/p>\n

Zast\u00e1nci t\u00e9to o\u010dkovac\u00ed metody, jako nap\u0159\u00a0B. Gavi, Vaccine Alliance \u2013 jej\u00edm\u017e je Gates Foundation zakl\u00e1daj\u00edc\u00edm \u010dlenem \u2013 naz\u00fdv\u00e1 n\u00e1plasti \u201ebudoucnost\u00ed o\u010dkov\u00e1n\u00ed, kde budou tato \u017eivot zachra\u0148uj\u00edc\u00ed opat\u0159en\u00ed aplikov\u00e1na bezbolestn\u011b, bez jehel a mo\u017en\u00e1 i bez vy\u0161kolen\u00e9ho zdravotnick\u00e9ho person\u00e1lu\u201c.<\/span><\/p>\n

\u201ePodpora inovac\u00ed v oblasti dod\u00e1v\u00e1n\u00ed vakc\u00edn je z\u00e1sadn\u00ed pro \u0159e\u0161en\u00ed p\u0159etrv\u00e1vaj\u00edc\u00edch nerovnost\u00ed v oblasti zdrav\u00ed,\u201c \u0159ekl v tiskov\u00e9 zpr\u00e1v\u011b James Goodson, spolu\u0159e\u0161itel studie a hlavn\u00ed \u0159e\u0161itel a epidemiolog v divizi glob\u00e1ln\u00ed imunizace CDC.<\/span><\/p>\n

Dodal, \u017ee studie je tak\u00e9 d\u016fle\u017eit\u00fdm krokem k licencov\u00e1n\u00ed z\u00e1plat.<\/span><\/p>\n

V\u00fdvoj\u00e1\u0159i tuto technologii propaguj\u00ed jako bezbolestnou \u2013 p\u016fsob\u00ed jako such\u00fd zip \u2013 a je termostabiln\u011bj\u0161\u00ed ne\u017e b\u011b\u017en\u00e9 vakc\u00edny.<\/span><\/p>\n

To by usnadnilo glob\u00e1ln\u00ed distribuci vakc\u00edn, p\u0159edev\u0161\u00edm v rozvojov\u00fdch oblastech, kde chyb\u00ed infrastruktura, jako je chlazen\u00ed a vy\u0161kolen\u00fd person\u00e1l.<\/span><\/p>\n

Trh s mikrojehli\u010dkovou vakc\u00ednou m\u00e1 hodnotu miliard<\/strong><\/span><\/p>\n

Gener\u00e1ln\u00ed \u0159editel spole\u010dnosti Micron Steven Damon \u0159ekl: „Spole\u010dnost Micron je nad\u0161en\u00e1 z dosa\u017een\u00ed d\u016fle\u017eit\u00e9ho miln\u00edku v budoucnosti bezinjek\u010dn\u00edch dod\u00e1vek nezbytn\u00fdch a potenci\u00e1ln\u011b \u017eivot zachra\u0148uj\u00edc\u00edch vakc\u00edn a l\u00e9\u010div s podporou nadace Bill & Melinda Gates Foundation a CDC.“<\/span><\/p>\n

Tato studie udr\u017euje spole\u010dnost v pop\u0159ed\u00ed uv\u00e1d\u011bn\u00ed produkt\u016f vakc\u00edn na b\u00e1zi mikro\u010dip\u016f na trh, \u0159ekl Damon.<\/span><\/p>\n

Gatesova nadace, CDC, Unicef, PATH \u2013 dal\u0161\u00ed organizace t\u011b\u017ece financovan\u00e1 Gatesem \u2013 a Georgia Research Alliance poskytly spole\u010dnosti Micron 40 milion\u016f dolar\u016f na v\u00fdvoj technologie mikrojehli\u010dkov\u00fdch z\u00e1plat.<\/span><\/p>\n

V roce 2017 Gatesova nadace ud\u011blila spole\u010dnosti Micron grant ve v\u00fd\u0161i 2,2 milionu dolar\u016f na v\u00fdvoj mikrojehli\u010dkov\u00e9 n\u00e1plasti pro MR vakc\u00ednu a dal\u0161\u00edch 900 milion\u016f dolar\u016f v roce 2022. Gates p\u0159edt\u00edm poskytl spole\u010dnosti Micron 2,5 milionu dolar\u016f na v\u00fdvoj mikrojehli\u010dkov\u00e9 n\u00e1plasti proti obrn\u011b jako sou\u010d\u00e1st \u00fasil\u00ed nadace o vym\u00fdtit obrnu.<\/span><\/p>\n

V posledn\u00edch m\u011bs\u00edc\u00edch Micron tak\u00e9 z\u00edskal zna\u010dn\u00e9 finan\u010dn\u00ed prost\u0159edky od investor\u016f, v\u010detn\u011b Global Health Investment Corporation a LTS Lohmann.\u00a0A p\u0159ed m\u00e9n\u011b ne\u017e dv\u011bma t\u00fddny, t\u011bsn\u011b p\u0159ed prezentac\u00ed v\u00fdsledk\u016f studie na konferenci Microneedles 2023, spole\u010dnost zajistila dal\u0161\u00ed investici ve v\u00fd\u0161i 3 milion\u016f USD od J2 Ventures, \u010d\u00edm\u017e se celkov\u00e9 financov\u00e1n\u00ed s\u00e9rie A zv\u00fd\u0161ilo na 17 milion\u016f USD.<\/span><\/p>\n

Financov\u00e1n\u00ed s\u00e9rie A je prvn\u00edm kolem kapit\u00e1lov\u00e9ho financov\u00e1n\u00ed pro za\u010d\u00ednaj\u00edc\u00ed spole\u010dnost pot\u00e9, co dos\u00e1hla ur\u010dit\u00e9ho \u00fasp\u011bchu s po\u010d\u00e1te\u010dn\u00edm financov\u00e1n\u00edm a p\u0159edch\u00e1z\u00ed IPO.<\/span><\/p>\n

Prob\u00edhaj\u00ed tak\u00e9 zkou\u0161ky o\u010dkovac\u00edch n\u00e1plast\u00ed na COVID-19, sez\u00f3nn\u00ed ch\u0159ipku a hepatitidu B, zat\u00edmco n\u00e1plasti na lidsk\u00fd papilomavirus, tyfus a rotavirus jsou v preklinick\u00e9m v\u00fdvoji.<\/span><\/p>\n

O\u010dek\u00e1v\u00e1 se, \u017ee samotn\u00fd trh s mikrojehli\u010dkovou vakc\u00ednou pro vakc\u00ednu proti ch\u0159ipce dos\u00e1hne do roku 2030 2,3 miliardy dolar\u016f.<\/span><\/p>\n

V lo\u0148sk\u00e9m roce Mark Prausnitz, Ph.D., spoluzakladatel a hlavn\u00ed v\u011bdeck\u00fd poradce spole\u010dnosti Micron Biomedical, p\u0159edstavil technologii spole\u010dnosti Micron na panelov\u00e9 diskuzi v B\u00edl\u00e9m dom\u011b na t\u00e9ma Inovace v dod\u00e1v\u00e1n\u00ed vakc\u00edn.<\/span><\/p>\n

Panel, kter\u00e9mu p\u0159edsedal Dr.\u00a0Francis Collins, tehdej\u0161\u00ed \u0159editel National Institutes of Health, prozkoumal \u201ecestu k inovativn\u00edm vakc\u00edn\u00e1m nov\u00e9 generace COVID-19 a technologi\u00edm dod\u00e1v\u00e1n\u00ed vakc\u00edn\u201c.<\/span><\/p>\n

\u201eTato technologie m\u00e1 revolu\u010dn\u00ed potenci\u00e1l zv\u00fd\u0161it dosah vakc\u00edn v oblastech s nedostatkem zdroj\u016f a b\u011bhem pandemi\u00ed,\u201c \u0159ekl Gavi David Hoey, prezident a gener\u00e1ln\u00ed \u0159editel biotechnologick\u00e9 spole\u010dnosti Vaxxas se s\u00eddlem v australsk\u00e9m Brisbane.<\/span><\/p>\n

Spole\u010dnost Hoey’s m\u00e1 ve studi\u00edch na lidech n\u00e1plasti na spalni\u010dky a zard\u011bnky, COVID-19 a sez\u00f3nn\u00ed ch\u0159ipku.<\/span><\/p>\n

Bezpe\u010dn\u00e9 a dob\u0159e sn\u00e1\u0161en\u00e9, \u017e\u00e1dn\u00e9 alergick\u00e9 reakce nebo souvisej\u00edc\u00ed z\u00e1va\u017en\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky<\/span><\/p>\n

Do klinick\u00e9 studie bylo za\u0159azeno 45 dosp\u011bl\u00fdch, 120 kojenc\u016f (ve v\u011bku 15-18 m\u011bs\u00edc\u016f) a 120 kojenc\u016f (ve v\u011bku 9-10 m\u011bs\u00edc\u016f), kte\u0159\u00ed byli n\u00e1hodn\u011b p\u0159i\u0159azeni k pod\u00e1n\u00ed vakc\u00edny proti MR bu\u010f pomoc\u00ed Micron’s microarray nebo subkut\u00e1nn\u00ed injekc\u00ed, tj. k\u016f\u017ee.<\/span><\/p>\n

Studie je\u0161t\u011b nebyla zve\u0159ejn\u011bna, ale v tiskov\u00e9 zpr\u00e1v\u011b Micron uv\u00e1d\u00ed, \u017ee mikro\u010dipov\u00e1 vakcinace se uk\u00e1zala jako bezpe\u010dn\u00e1 a dob\u0159e tolerovan\u00e1, bez alergick\u00fdch reakc\u00ed nebo souvisej\u00edc\u00edch z\u00e1va\u017en\u00fdch ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f.<\/span><\/p>\n

Studie uv\u00e1d\u00ed podobnou m\u00edru s\u00e9roprotekce p\u0159ibli\u017en\u011b 90 % nebo vy\u0161\u0161\u00ed po 42 dnech pro skupiny, kter\u00e9 dost\u00e1valy mikro\u010dipy a subkut\u00e1nn\u00ed injekce.<\/span><\/p>\n

„Obecn\u011b rodi\u010de velmi pozitivn\u011b vn\u00edmali mo\u017enost o\u010dkovat sv\u00e9 mal\u00e9 d\u011bti bez jehly,“ \u0159ekl Damon.<\/span><\/p>\n

Transderm\u00e1ln\u00ed n\u00e1plasti se pou\u017e\u00edvaj\u00ed pro stavy, jako je kinet\u00f3za, od roku 1979, ale mnoho typ\u016f l\u00e9k\u016f nem\u016f\u017ee b\u00fdt aplikov\u00e1no p\u0159es k\u016f\u017ei, proto\u017ee k\u016f\u017ee je \u00fa\u010dinnou bari\u00e9rou.<\/span><\/p>\n

Podle Gaviho se v\u00fdvoj\u00e1\u0159 vakc\u00edn Prausnitz l\u00e9ta sna\u017eil naj\u00edt zp\u016fsoby, jak prolomit ko\u017en\u00ed bari\u00e9ru, aby se usnadnilo pod\u00e1v\u00e1n\u00ed l\u00e9k\u016f, ale a\u017e pot\u00e9, co za\u010dal pracovat s lidmi, kte\u0159\u00ed m\u011bli znalosti o po\u010d\u00edta\u010dov\u00fdch mikro\u010dipech, dok\u00e1zal naj\u00edt zp\u016fsoby, jak prolomit p\u0159irozen\u00e1 bari\u00e9ra, kter\u00e1 pronik\u00e1 do poko\u017eky.<\/span><\/p>\n

Ka\u017ed\u00e1 vakc\u00edna pak pot\u0159ebuje svou vlastn\u00ed formulaci, kter\u00e1 m\u016f\u017ee s touto technologi\u00ed fungovat.<\/span><\/p>\n

Posun od \u201evelk\u00fdch klinick\u00fdch studi\u00ed netestovan\u00fdch nebo neschv\u00e1len\u00fdch l\u00e9k\u016f k rozv\u00edjej\u00edc\u00edm se trh\u016fm<\/span><\/p>\n

Podle Fierce Pharma odr\u00e1\u017e\u00ed rozhodnut\u00ed Micronu prov\u00e9st v\u016fbec prvn\u00ed zkou\u0161ku nov\u00e9 technologie u d\u011bt\u00ed v Africe<\/strong> p\u0159esv\u011bd\u010den\u00ed, \u017ee mikrojehli\u010dkov\u00e1 technologie je zvl\u00e1\u0161t\u011b vhodn\u00e1 pro dod\u00e1v\u00e1n\u00ed vakc\u00edn v t\u00e9to \u010d\u00e1sti sv\u011bta.<\/span><\/p>\n

\u201eTechnologie mikrojehli\u010dek je uzn\u00e1v\u00e1na jako kl\u00ed\u010dov\u00e1 sou\u010d\u00e1st kontroly spalni\u010dek v subsaharsk\u00e9 Africe i jinde.\u00a0Je to mimo jin\u00e9 d\u00e1no potenci\u00e1ln\u011b jednoduchou administrativou, ni\u017e\u0161\u00edmi n\u00e1roky na chlad\u00edc\u00ed \u0159et\u011bzec a eliminac\u00ed ostrohrann\u00e9ho odpadu\u201c, \u0159\u00edk\u00e1 Dr.\u00a0Ed Clarke v prohl\u00e1\u0161en\u00ed.<\/span><\/p>\n

Clarke, kter\u00fd prov\u00e1d\u00ed v\u00fdzkum na London School of Hygiene and Tropical Medicine a vedl studii, tak\u00e9 z\u00edskal finan\u010dn\u00ed prost\u0159edky od Gates Foundation na studium dal\u0161\u00edch vakc\u00edn v Gambii.<\/span><\/p>\n

Mnoho v\u011bdc\u016f vyj\u00e1d\u0159ilo znepokojen\u00ed nad t\u00edm, \u017ee v\u00fdzkum prov\u00e1d\u011bn\u00fd mezin\u00e1rodn\u00edmi organizacemi na glob\u00e1ln\u00edm jihu, a zejm\u00e9na Gates Foundation, postr\u00e1d\u00e1 odpov\u011bdnost a m\u016f\u017ee m\u00edt za n\u00e1sledek v\u00e1\u017en\u00e9 po\u0161kozen\u00ed testovan\u00e9 populace.<\/span><\/p>\n

Podle \u010dl\u00e1nku zve\u0159ejn\u011bn\u00e9ho v Annual Survey of International and Comparative Law: \u201eTyto zdravotn\u00ed kampan\u011b [v Indii a Africe] pod rou\u0161kou z\u00e1chrany \u017eivot\u016f p\u0159esunuly rozs\u00e1hl\u00e9 klinick\u00e9 studie neprok\u00e1zan\u00fdch nebo neschv\u00e1len\u00fdch l\u00e9k\u016f<\/strong> do rozvojov\u00fdch zem\u00ed, kde pod\u00e1v\u00e1n\u00ed l\u00e9k\u016f je m\u00e9n\u011b regulovan\u00e9 a levn\u011bj\u0161\u00ed.<\/span><\/p>\n

Redak\u010dn\u00ed rada Lancet tak\u00e9 vznesla ot\u00e1zky ohledn\u011b Gatesem financovan\u00e9ho v\u00fdzkumu v oblastech s n\u00edzk\u00fdmi p\u0159\u00edjmy, p\u0159i\u010dem\u017e uvedla omezenou transparentnost nadace a obrovskou moc vyu\u017e\u00edvat sv\u00e9 prost\u0159edky k \u0159\u00edzen\u00ed zdravotn\u00edch program\u016f a v\u00fdzkumu.<\/span><\/p>\n<\/div>\n<\/div>\n

\n
\n

ZDROJ<\/a><\/span><\/h3>\n<\/div>\n<\/div>\n

 <\/p>\n

 <\/p>\n

\"\"<\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Biotechnologick\u00e1 spole\u010dnost se s\u00eddlem v Atlant\u011b minul\u00fd t\u00fdden ozn\u00e1mila, \u017ee s podporou nadace Bill &…<\/p>\n","protected":false},"author":2,"featured_media":29241,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[7],"tags":[511,245,276,651],"_links":{"self":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts\/29240"}],"collection":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/comments?post=29240"}],"version-history":[{"count":0,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts\/29240\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/media\/29241"}],"wp:attachment":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/media?parent=29240"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/categories?post=29240"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/tags?post=29240"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}